What's in Vertex Pharmaceuticals Incorporated's pipeline?

Vertex Pharmaceuticals Incorporated has 65 drugs in our index: 9 marketed, 0 filed, 19 in Phase 3, 15 in Phase 2, 22 in Phase 1.

Which companies overlap with Vertex Pharmaceuticals Incorporated's portfolio?

Top competitors by shared drug class: University of Alabama at Birmingham, Ain Shams University, Hoffmann-La Roche, Chiesi Farmaceutici S.p.A., Assistance Publique - Hôpitaux de Paris.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/vertex-pharmaceuticals-incorporated.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Vertex Pharmaceuticals Incorporated — Portfolio Competitive Intelligence Brief

Vertex Pharmaceuticals Incorporated pipeline: 9 marketed, 0 filed, 19 Phase 3, 15 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9 marketed 0 filed 19 Phase 3 15 Phase 2 22 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
IVA	IVA	marketed	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)	Pulmonary/Respiratory
SUZ	SUZ	marketed	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)	Pulmonary/Respiratory
Ribavirin (Copegus®)	Ribavirin (Copegus®)	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; inosine monophosphate dehydrogenase (IMPDH)	Virology/Infectious Disease
LUM/IVA	LUM/IVA	marketed	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)	Respiratory / Genetic disease
Immunosuppressant Regimen	Immunosuppressant Regimen	marketed
Suzetrigine (SUZ)	Suzetrigine (SUZ)	marketed	Selective sodium channel inhibitor	Voltage-gated sodium channels (Nav)	Pain management / Neurology
Pegylated Interferon Alfa 2a	Pegylated Interferon Alfa 2a	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)	Immunology, Virology, Oncology
TEZ	TEZ	marketed	CFTR corrector	CFTR (cystic fibrosis transmembrane conductance regulator)	Pulmonary/Genetic Disorders
LUM	LUM	marketed	Tankyrase inhibitor / Wnt signaling modulator	Tankyrase (TNKS1/TNKS2)	Gastroenterology
VX-880	VX-880	phase 3			Ophthalmology
VNZ/TEZ/D-IVA	VNZ/TEZ/D-IVA	phase 3	CFTR modulator	CFTR	Cystic Fibrosis
CTX001	CTX001	phase 3	CAR-T cell therapy / Gene-edited T-cell therapy	BCMA (B-cell maturation antigen) / Tumor-associated antigens	Oncology / Hematologic Malignancies

Therapeutic area mix

Pulmonology · 3
Respiratory · 3
Pulmonary/Respiratory · 3
Cystic Fibrosis · 2
Oncology / Hematologic Malignancies · 1
Ophthalmology · 1
Other · 1
Pain management / Neurology · 1
Pulmonary / Genetic Disorders · 1
Pulmonary/Genetic Disorders · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

University of Alabama at Birmingham · 2 shared drug classes
Ain Shams University · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Chiesi Farmaceutici S.p.A. · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Daiichi Sankyo Co., Ltd. · 1 shared drug class
Children's Hospital Medical Center, Cincinnati · 1 shared drug class
Dr. Conrado Fernandez · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vertex Pharmaceuticals Incorporated:

Cite this brief

Drug Landscape (2026). Vertex Pharmaceuticals Incorporated — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vertex-pharmaceuticals-incorporated. Accessed 2026-05-16.